Status: Recruiting
A Study to Evaluate the Safety, Tolerability, and Preliminary Efficacy of BRII-5395 in Combination With Sintilimab and Bevacizumab in Advanced Hepatitis B Virus Related Hepatocellular Carcinoma
This early phase (Phase 1) study will evaluate BRII 5395, administered in combination with two approved anticancer agents, sintilimab and bevacizumab, in patients with advanced liver cancer caused by chronic hepatitis B virus (HBV) infection. The primary objective of the study is to assess the safety and tolerability of the combination therapy, as well as to explore preliminary evidence of clinical benefit.
Participants needed: 21
Trial details
Phase: Phase 1Age: 18-70Biological sex: AllType: InterventionalSponsor: Cancer Institute and Hospital, Chinese Academy of Medical SciencesUpdated: Aug 31, 2026Locations: 1
Eligibility criteria
Diagnosis of locally advanced or metastatic HCC that is deemed unsuitable for su... [+5]
Any systemic anticancer therapy within specified period prior to the first dose... [+6]